|  |
| --- |
| Supplementary Table S1. Mite antigen allergy tests performed in patients per analysis set. |
| **Item** | **Safety analysis set (n = 526)** | **Effectiveness analysis set (n = 371)** |
| Mite antigen allergy test Noa  Yes Unknowna | 9 (1.7)513 (97.5)4 (0.8) | 7 (1.9)362 (97.6)2 (0.5) |
| Skin reaction test Negative Positive | 1 (0.2)20 (3.9) | 0 (0)15 (4.1) |
| CAP-RAST 0 1 2 3 4 5 6 | 0 (0)8 (1.6)37 (7.2)79 (15.4)101 (19.7)71 (13.8)103 (20.1) | 0 (0)7 (1.9)29 (8.0)60 (16.6)75 (20.7)48 (13.3)70 (19.3) |
| MAST-33 Class 0 Class 1 Class 2 Class 3 Class 4 Class 5 Class 6 | 0 (0)1 (0.2)11 (2.1)14 (2.7)9 (1.8)3 (0.6)8 (1.6) | 0 (0)0 (0)9 (2.5)6 (1.7)6 (1.7)2 (0.6)5 (1.4) |
| View-36 Class 0 Class 1 Class 2 Class 3 Class 4 Class 5 Class 6 | 0 (0)1 (0.2)8 (1.6)10 (1.9)11 (2.1)11 (2.1)7 (1.4) | 0 (0)0 (0)6 (1.7)7 (1.9)8 (2.2)7 (1.9)3 (0.8) |
| Data are expressed as n (%). a Patients had been diagnosed at other hospital before entering the survey study.CAP-RAST, ImmunoCAP Specific IgE blood test (CAP)-radioallergosorbent test (RAST); MAST-33, Multiple Antigen Simultaneous Test; View-36, Multiple (36) antigen test. |